在患有急性淋巴细胞白血病的儿童中,评估FTO多态性在与6-默卡普图氨酸相关的不耐受性中
Minu Singh1, Divya Bhaskar1, Prateek Bhatia1
1Haematology-Oncology Unit, Department of Paediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Cancer chemotherapy and pharmacology
|May 31, 2023
概括
在患有急性淋巴细胞白血病 (ALL) 的儿童中,FTO基因 (FTO-rs16952570) 的遗传变异与提奥普林诱导的骨髓抑制或肝毒性无关. 这一发现表明,FTO-rs16952570在这个患者群体中不是 thiopurine 毒性的预测生物标志物.
科学领域:
- 药物基因组学 药物基因组学
- 在瘤学瘤学.
- 遗传学 遗传学是一种遗传学.
背景情况:
- 提奥普林类药物,如6-美卡普普林 (6MP),对于急性淋巴细胞白血病 (ALL) 维持治疗至关重要.
- 遗传变异,特别是在FTO基因中,已与氨酸诱导的骨髓抑制有关.
研究的目的:
- 调查FTO基因变异 (rs79206939和rs16952570) 之间的关联,以及在患有ALL的印度儿童中诱导类皮氨酸骨髓抑制和肝毒性的风险.
主要方法:
- 在174名患有ALL的印度儿童中,FTO编码 (p.Ala134Thr,rs79206939) 和内部 (rs16952570) 变异的基因定型.
- 分析FTO基因型与氨酸毒性之间的相关性,包括骨髓抑制和肝毒性.
主要成果:
- 没有FTO-rs79206939的变种. 在FTO-rs16952570多态的流行率为18.4%.
- 虽然较高比例的CC基因型携带者能够耐受6 - 墨卡普图 (6MP) 的起始剂量,但在FTO-rs16952570基因型和白细胞总数,绝对中性粒细胞数或血小板数之间没有发现显著的相关性.
- 在FTO-rs16952570基因型和化疗中断,发烧性中性质减退或肝毒性之间没有发现显著的关联.
结论:
- 在儿童ALL患者中,FTO-rs16952570基因的多态性并没有与氨酸相关的毒性相关.
- 在这个人群中,FTO-rs16952570不太可能是 thiopurine 毒性的预测生物标志物.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...


